Cancer immunotherapies aim to harness the immune system to fight tumours. Carisma Therapeutics is taking a novel approach to cancer immunotherapy by utilizing macrophages recruited to solid tumours as part of an immune response. Carisma aims to use chimeric antigen receptor (CAR) macrophages to prime the immune system to kill tumours. One of Carisma’s goals …Read More >
TiCARos Therapeutics has leveraged the expertise of their team of immunologists from Seoul National University, College of Medicine to develop a promising pipeline of nextgeneration immunotherapies for intractable haematologic malignancies and advanced solid tumours. TiCARos’ mission is to create medication based on science. TiCARos was founded by two leading T cell immunologists, who have built …Read More >